Antidepressants & ARVs

Drug-drug interactions between Antidepressants & ARVs


              Potential elevated exposure of the antidepressant      
              Potential decreased exposure of the antidepressant
            No significant effect
D              Potential decreased exposure of ARV drug
E              Potential elevated exposure of ARV drug
ATV/c     ATV co-formulated with COBI (300/150 mg qd)
DRV/c     DRV co-formulated with COBI (800/150 mg qd)

Numbers refer to increased or decreased AUC as observed in drug-drug interaction studies

SSRI  =  selective serotonin reuptake inhibitors
SNRI  =  serotonin and norepinephrine reuptake inhibitors
TCA   =  tricyclic antidepressants
TeCA =  tetracyclic antidepressants


Interactions with ZDV
No clinically relevant interactions expected with ZDV and antidepressants



  1. ECG monitoring is recommended      
  2. Caution as both drugs can induce QT interval prolongation
  3. No PK change with unboosted ATV
  4. The European SmPC recommends DTG 50 mg bid in persons without INSTI resistance. The US Prescribing Information recommends that co-administration should be avoided as there are insufficient data to make dosing recommendations


Further information
For additional drug-drug interactions and for more detailed pharmacokinetic interaction data and dosage adjustments, please refer to (University of Liverpool).